Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients.
extracellular matrix metalloproteinase inducer (EMMPRIN)
liquid biopsy
macrophage migration inhibitory factor (MIF)
protumoral M2-like tumor associated microglia/macrophages (TAMs)
retinoblastoma
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
10
02
2022
received:
08
09
2021
accepted:
03
03
2022
pubmed:
8
3
2022
medline:
7
6
2022
entrez:
7
3
2022
Statut:
ppublish
Résumé
The microenvironment of retinoblastoma, the solid malignancy of the developing retina, is immunosuppressive. To study the interactions between tumor-associated microglia/macrophages (TAMs) and tumor cells in retinoblastomas, we analyzed immunohistochemistry markers in 23 patient samples and characterized 105 secreted cytokines of 11 retinoblastoma cell models in culture. We detected profuse infiltration of CD163
Substances chimiques
Basigin
136894-56-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-339Informations de copyright
© 2022 The Pathological Society of Great Britain and Ireland.
Références
Munier FL, Beck-Popovic M, Chantada GL, et al. Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity". Prog Retin Eye Res 2019; 73: 100764.
Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nat Commun 2021; 12: 5578.
Xu XL, Fang Y, Lee TC, et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 2009; 137: 1018-1031.
Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-334.
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med 2019; 11: eaat9321.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019; 18: 197-218.
Miracco C, Toti P, Gelmi MC, et al. Retinoblastoma is characterized by a cold, CD8+ cell poor, PD-L1- microenvironment, which turns into hot, CD8+ cell rich, PD-L1+ after chemotherapy. Invest Ophthalmol Vis Sci 2021; 62: 6.
Singh L, Singh MK, Rizvi MA, et al. Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. Cancer Immunol Immunother 2020; 69: 1087-1099.
Ganesan B, Parameswaran S, Sharma A, et al. Clinical relevance of B7H3 expression in retinoblastoma. Sci Rep 2020; 10: 10185.
Ge Z, Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front Oncol 2020; 10: 590941.
Choi S, Kim HR, Leng L, et al. Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. J Immunol 2012; 189: 3905-3913.
Abe R, Peng T, Sailors J, et al. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001; 166: 747-753.
Ghoochani A, Schwarz MA, Yakubov E, et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene 2016; 35: 6246-6261.
Ladányi A, Tímár J. Immunologic and immunogenomic aspects of tumor progression. Semin Cancer Biol 2020; 60: 249-261.
Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8: 369-380.
Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-1274.
Porta C, Consonni FM, Morlacchi S, et al. Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSCs. Cancer Res 2020; 80: 2874-2888.
Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology 2015; 122: 1173-1179.
Galardi A, Colletti M, Lavarello C, et al. Proteomic profiling of retinoblastoma-derived exosomes reveals potential biomarkers of vitreous seeding. Cancers (Basel) 2020; 12: 1555.
Berry JL, Xu L, Murphree AL, et al. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. JAMA Ophthalmol 2017; 135: 1221-1230.
Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012; 96: 1078-1083.
Ma B, Lei X, Guan Y, et al. Maintenance of retinal cancer stem cell-like properties through long-term serum-free culture from human retinoblastoma. Oncol Rep 2011; 26: 135-143.
Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, et al. Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Lett 2016; 380: 10-19.
Pascual-Pasto G, Olaciregui NG, Opezzo JAW, et al. Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. J Control Release 2017; 264: 34-44.
Asnaghi L, White DT, Key N, et al. ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene 2019; 38: 2056-2075.
Winter U, Ganiewich D, Ottaviani D, et al. Genomic and transcriptomic tumor heterogeneity in bilateral retinoblastoma. JAMA Ophthalmol 2020; 138: 569-574.
Li X, Zhang Y, Ma W, et al. Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma. Cancer Immunol Immunother 2020; 69: 535-548.
Sun L, Zhang X, Song Q, et al. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett 2021; 500: 132-146.
Shiraki A, Kotooka N, Komoda H, et al. Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep 2016; 5: 290-295.
Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019; 20: 163-172.
Adithi M, Nalini V, Kandalam M, et al. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol 2007; 29: 399-405.
Ratnam NM, Peterson JM, Talbert EE, et al. NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J Clin Invest 2017; 127: 3796-3809.
Berry JL, Xu L, Kooi I, et al. Genomic cfDNA analysis of aqueous humor in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retinoblastoma. Mol Cancer Res 2018; 16: 1701-1712.
Abramson DH, Mandelker D, Francis JH, et al. Retrospective evaluation of somatic alterations in cell-free DNA from blood in retinoblastoma. Ophthalmol Sci 2021; 1: 100015.
Buechler C, Ritter M, Orsó E, et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000; 67: 97-103.
Yaddanapudi K, Putty K, Rendon BE, et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol 2013; 190: 2984-2993.
Figueiredo CR, Azevedo RA, Mousdell S, et al. Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma. Front Immunol 2018; 9: 1132.
Parareda A, Català J, Carcaboso AM, et al. Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmol 2014; 92: 209-215.
Usui Y, Okunuki Y, Hattori T, et al. Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. Invest Ophthalmol Vis Sci 2006; 47: 4607-4613.
Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015; 6: e1792.
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
Zhang R, Song Y-N, Duo X, et al. Retinoblastoma cell-derived Twist protein promotes regulatory T cell development. Cancer Immunol Immunother 2021; 70: 1037-1048.
Garcia GA, Topping KL, Mruthyunjaya P, et al. Pseudoprogression of metastatic melanoma to the orbit with pembrolizumab. Ophthal Plast Reconstr Surg 2020; 36: e36-e40.
Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 2019; 25: 2560-2574.
Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell 2019; 35: 221, .e8-237.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
Efremova M, Vento-Tormo M, Teichmann SA, et al. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc 2020; 15: 1484-1506.
Noël F, Massenet-Regad L, Carmi-Levy I, et al. Dissection of intercellular communication using the transcriptome-based framework ICELLNET. Nat Commun 2021; 12: 1089.